Brown AND Burk Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Brown AND Burk Limited Pharmaceutical Import Records from India — 3 Products, $1.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Brown AND Burk Limited — Pharmaceutical Importer Profile (2026) | 3 Products, $1.0M Trade | TransData Nexus

Brown AND Burk Limited

Pharmaceutical Importer · United Kingdom · CNS & Psychiatric Focus · $1.0M Total Trade · DGFT Verified

Brown AND Burk Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $1.0M across 3 products in 3 therapeutic categories. Based on 20 verified import shipments from Indian Customs (DGFT) records, Brown AND Burk Limited is the #1 buyer in 1 product including Clarithromycin. Brown AND Burk Limited sources from 1 verified Indian supplier, with Micro Labs Limited accounting for 100.0% of imports.

Brown AND Burk Limited — Import Portfolio & Supplier Network

Brown AND Burk Limited import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Brown AND Burk Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$5.7M	228	100.0%

Brown AND Burk Limited sources from 1 verified Indian supplier across 116 distinct formulations. The sourcing is highly concentrated — Micro Labs Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Brown AND Burk Limited Import?

Formulation	Value	Ships
Gabapentin brown burk 300MG capsules	$450.0K	9
Gabapentin brown & burk 100MG capsules	$400.0K	8
Fluoxetine 20MG capsules (3x10s) - tax	$298.4K	6
Gabapentin brown & burk 400MG capsules	$294.0K	6
Carbocisteine capsules 375MG hard	$218.3K	5
Phenoxymethylpenicillin 250MG film	$207.6K	8
Gabapentin brown&bulk 300MG capsules	$200.0K	4
Carbocisteine capsules 375 MG, hard	$200.0K	4
Ramipril 2.5MG capsules ( (in bb livery)	$178.6K	10
Gabapentin brown&bulk 100MG capsules	$150.0K	3
Clarithromycin film - coated tablets	$150.0K	3
Escitalopram 20MG film coated tablets	$145.0K	3
Amoxicillin sugar free 250MG/5ML	$127.4K	3
Ramipril 10MG capsules ( (bb livery) )	$111.0K	3
Simvastatin 40MG film coated tablets	$107.0K	3

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluoxetine	CNS & Psychiatric	$600.0K	12	0.3%	3
2	Clarithromycin	Antibiotics	$200.0K	4	0.2%	1
3	Flucloxacillin	Advanced Antibiotics	$200.0K	4	0.5%	14

Brown AND Burk Limited imports 3 pharmaceutical products across 3 categories into United Kingdom totaling $1.0M. The company is the #1 buyer for 1 product: Clarithromycin.

Brown AND Burk Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Brown & Burk UK Limited (BBUK) is an independent generic pharmaceutical company established in 2000, headquartered in Ruislip, Middlesex, United Kingdom. The company specializes in the manufacturing, marketing, and distribution of generic medicinal products across the UK and Europe. BBUK is committed to providing high-quality, affordable healthcare solutions, emphasizing a reliable and controlled pharmaceutical supply chain.

The company's registered office is located at Micro House, 5 Marryat Close, Hounslow, TW4 5DQ, United Kingdom. BBUK holds a Wholesale Distribution Authorisation (WDA) from the Medicines and Healthcare products Regulatory Agency (MHRA), authorisation number UK WDA(H) 25298, which permits the wholesale distribution of medicinal products for human use. (cms.mhra.gov.uk)

2Distribution Network

BBUK operates from two primary locations:

Micro House, Bury Street, Ruislip, HA4 7TL, United Kingdom: This site is authorized for procurement, holding, supply, and export of medicinal products. (cms.mhra.gov.uk)

Micro House, 5 Marryat Close, Hounslow, TW4 5DQ, United Kingdom: This location is authorized for procurement, supply, and export of medicinal products. (cms.mhra.gov.uk)

While specific details about BBUK's logistics capabilities and geographic coverage beyond the United Kingdom are not publicly disclosed, the company's strategic alliances with large pharmaceutical manufacturing companies and research-based organizations suggest a robust distribution network within the UK and potential reach across Europe.

3Industry Role

BBUK functions as a primary wholesaler and distributor of generic pharmaceutical products within the United Kingdom. The company imports finished pharmaceutical formulations from various suppliers, including those in India, to supply the UK market. BBUK's role encompasses the procurement, storage, and distribution of these products to healthcare providers, ensuring a steady supply of essential medicines.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Brown AND Burk Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

BBUK's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a single supplier:

MICRO LABS LIMITED: BBUK has imported $5.7 million worth of products from MICRO LABS LIMITED, comprising 228 shipments, accounting for 100% of its imports from India.

This single-source dependency may present risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent volume of shipments and the long-term nature of the relationship suggest a stable and reliable partnership. The absence of alternative suppliers indicates that BBUK may prioritize supplier reliability and product quality over diversification.

2Supply Chain Resilience

BBUK's supply chain resilience appears to be robust, given the long-standing relationship with MICRO LABS LIMITED. The consistent importation of 116 unique formulations indicates a diverse product portfolio, which can mitigate risks associated with dependency on a single supplier. However, the lack of backup suppliers for these formulations suggests potential vulnerabilities in the event of supply chain disruptions. The stability of shipping routes and adherence to regulatory compliance by MICRO LABS LIMITED further contribute to the resilience of BBUK's supply chain.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

The Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory body overseeing the pharmaceutical industry in the United Kingdom. The MHRA is responsible for ensuring that medicines and medical devices meet required standards of safety, quality, and efficacy. Key legislation governing pharmaceutical imports includes the Human Medicines Regulations 2012, which outlines the authorization, manufacture, distribution, and sale of human medicines in the UK.

The MHRA's role encompasses licensing and inspecting businesses involved in the manufacture, production, and distribution of medicines, as well as monitoring the medicinal products that these businesses produce. The agency also ensures compliance with Good Manufacturing Practice (GMP) standards, which are essential for maintaining the quality and safety of pharmaceutical products. (assets.publishing.service.gov.uk)

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the UK are stringent. Importers must hold a valid Wholesale Distribution Authorisation (WDA) issued by the MHRA, which permits the wholesale distribution of medicinal products for human use. BBUK holds such an authorisation, number UK WDA(H) 25298, which covers procurement, holding, supply, and export operations. (cms.mhra.gov.uk)

Brown AND Burk Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

BBUK's product strategy focuses on high-quality, EU GMP-compliant generic pharmaceuticals across various therapeutic categories. The company's portfolio includes medications in the CNS & Psychiatric, Antibiotics, and Advanced Antibiotics categories, indicating a strategic emphasis on addressing prevalent health conditions in the UK. The importation of specific products like Fluoxetine, Clarithromycin, and Flucloxacillin aligns with market demand and therapeutic needs.

2Sourcing Profile

BBUK's sourcing strategy is centered on importing finished pharmaceutical formulations from a single supplier, MICRO LABS LIMITED. This approach suggests a focus on supplier reliability and product quality. The company's portfolio concentration, with the top five products accounting for 100% of imports, indicates a streamlined procurement process. While this strategy may limit diversification, it reflects BBUK's commitment to maintaining a consistent and high-quality product offering.

3Market Positioning

BBUK serves the UK pharmaceutical market by supplying generic medicines to various segments, including retail pharmacies, hospitals, and government tenders. The company's focus on high-quality, affordable healthcare solutions positions it as a key player in the wholesale distribution of generic pharmaceuticals. BBUK's strategic alliances and efficient supply chain management further enhance its market presence and competitiveness.

Seller's Guide — How to Become a Supplier to Brown AND Burk Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For new Indian suppliers, there is a realistic opportunity to partner with BBUK by meeting the company's quality standards and regulatory requirements. Diversifying BBUK's supplier base could enhance supply chain resilience and reduce risks associated with single-source dependency. Indian exporters can explore this opportunity by ensuring compliance with EU GMP standards and engaging in discussions with BBUK to establish mutually beneficial partnerships.

2Requirements & Qualifications

Indian exporters seeking to supply BBUK and the UK market must ensure compliance with EU GMP standards, as recognized by the MHRA. Additionally, obtaining a Wholesale Distribution Authorisation (WDA) from the MHRA is essential for importing medicinal products into the UK. Adherence to labeling requirements, including the use of English language and compliance with UK regulations, is also mandatory. Ensuring product quality through batch testing and stability assessments is crucial for market acceptance.

3How to Approach

Frequently Asked Questions — Brown AND Burk Limited

What products does Brown AND Burk Limited import from India?

Brown AND Burk Limited imports 3 pharmaceutical products across 3 categories. Top imports: Fluoxetine ($600.0K), Clarithromycin ($200.0K), Flucloxacillin ($200.0K).

Who supplies pharmaceuticals to Brown AND Burk Limited from India?

Brown AND Burk Limited sources from 1 verified Indian suppliers. The primary supplier is Micro Labs Limited (100.0% of imports, $5.7M).

What is Brown AND Burk Limited's total pharmaceutical import value?

Brown AND Burk Limited's total pharmaceutical import value from India is $1.0M, based on 20 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Brown AND Burk Limited focus on?

Brown AND Burk Limited imports across 3 categories. The largest: CNS & Psychiatric (60.0%), Antibiotics (20.0%), Advanced Antibiotics (20.0%).

Get Full Brown AND Burk Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.